Twitter summary: Using a #T2D therapy for #T1D, Lexicon & JDRF partner up for phase 2 trial of SGLT-2/SGLT-1 dual inhibitor drug On July 9, Lexicon announced a...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
42 readers recommended
Twitter summary: Lilly’s new basal #insulin Peglispro superior to Sanofi’s Lantus in A1c reduction, though some potential liver safety and hypo concerns On September 4,...
38 readers recommended
On June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe...
44 readers recommended
Twitter Summary: Novo Nordisk’s Xultophy gets positive recommendation in Europe, full approval to hopefully come soon! On July 25, Novo Nordisk announced that the...
43 readers recommended
Twitter summary: After huge anticipation for this innovative drug combination, Novo Nordisk’s Xultophy received approval in Europe for #T2D, 1 st ever basal insulin/GLP-...
28 readers recommended
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
58 readers recommended
How many different factors can affect blood glucose? See the 22 things that can change your blood sugar in the short-term...
36 readers recommended
Twitter Summary: FDA approves Trulicity for #T2D, 1 st ready-to-use once-weekly GLP-1 agonist in the US, with a patient-friendly “auto-injector” – launch for later this...
39 readers recommended
On June 17, Boehringer Ingelheim (BI) and Lilly announced the resubmission to the FDA of the SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of type 2...
38 readers recommended
Twitter summary: FDA grants “tentative approval” to Lilly/BI’s Basaglar – new insulin option will be an alternative to Lantus in future On August 18, Eli Lilly and...
35 readers recommended
Twitter Summary: @LillyPad receives EU approval for Humalog 200 units/ml Kwikpen – 600 units of insulin in a 3 ml pen, hopeful US resubmission late 2014 Eli Lilly...
37 readers recommended
Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
38 readers recommended
Twitter summary: New Sanofi & MannKind partnership to bring inhaled insulin Afrezza to US in early 2015, presumably primarily to type 2 patients to start On August...
31 readers recommended
Twitter summary: Roche’s Lucentis granted “priority review” from FDA – decision by Feb. 2015, potentially 1 st ever eye medicine for diabetic retinopathy Roche recently...
42 readers recommended
Advances in type 1 diabetes at The American Diabetes Association 74th Scientific Sessions
35 readers recommended
Twitter summary: FDA approves first-ever SGLT-2 inhibitor/metformin combo pill in the US – Janssens’s Invokamet launched Aug 18 On August 8, Janssen announced the FDA...
41 readers recommended
Twitter summary: Contrave launched in the US w/ weight support program + savings/loyalty programs offer new option for patients Two healthcare companies, Orexigen and...
50 readers recommended
On June 19, Novo Nordisk announced the launch of its FlexTouch pen for the long-acting basal insulin Levemir (insulin detemir). FlexTouch, which has been approved in...
35 readers recommended
Twitter summary: Exciting positive vote for #liraglutide #emdac on possible new therapy for #obesity! Plus, our favorite open public hearing yet. Yesterday on September...
48 readers recommended
Twitter summary: FDA approves Xigduo XR – first once-daily SGLT-2 inhibitor/metformin fixed dose combo in the US AstraZeneca recently announced that the FDA approved...